With 5 years of follow up, we observed a dose-response relationship between HCC and serum level of AFB1-albumin adducts (51) and urinary AFB1 metabolites (52) among those who had null genotypes of GSTM1 and T1 but not among those who had non-null genotypes. This evidence concerns the gene ALB and hepatocellular carcinoma.